Epcoritamab and Rituximab for First-line Follicular Lymphoma
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Recruiting · NCT05783609 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epcoritamab and Rituximab for First-line Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-05-22 | NCT05783609 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Genmab | 54 |
| Reid Merryman, MD | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Icahn School of Medicine at Mount Sinai Hospital | New York | United States | 2 |
| Medical College of Wisconsin | Milwaukee | United States | 483 |
| The Ohio State University Wexner Medical Center | Columbus | United States | 102 |
| University of Rochester Medical Center | Rochester | United States | 162 |